<DOC>
	<DOCNO>NCT00121550</DOCNO>
	<brief_summary>A grow body evidence link Chlamydia pneumoniae progression coronary heart disease . The purpose study determine positive negative effect 14 day treatment clarithromycin 500 mg daily patient already suffer stable coronary heart disease . The participant follow least two year treatment . Abbott Laboratories supply Clarithromycin placebo tablet .</brief_summary>
	<brief_title>The CLARICOR Trial : Effect Clarithromycin Mortality Morbidity Patients With Ischemic Heart Disease</brief_title>
	<detailed_description>Basic science suggest fundamental role inflammation mediate stage coronary heart disease ( CHD ) , large number clinical study report association marker inflammation CHD . Consequently , infectious agent propose promoter atherosclerosis and/or acute coronary syndrome ( ACS ) . Many study suggest relation Chlamydia pneumoniae ( C. pneumoniae ) infection CHD , C. pneumoniae demonstrate atherosclerotic tissue . Macrolide antibiotic effective eradication C. pneumoniae atherosclerotic plaque . Two small trial show significant beneficial effect macrolides cardiovascular morbidity patient ACS . To corroborate extend finding , undertook randomise , placebo-controlled trial clarithromycin patient stable CHD order test hypothesis intervention macrolide would reduce cardiovascular risk regard mortality morbidity .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>patient age 18 85 year previous acute myocardial infarction ( AMI ) previous present angina pectoris sign informed concent AMI unstable angina pectoris within last three month revascularisation ( PTCA CABG ) within precede six month severe heart failure ( New York Heart Association ( NYHA ) functional class IV ) know impaired renal hepatic function active malignancy intolerance macrolides treatment methylxanthines , carbamazepine , cisapride , astemizole , terfenadine , coumarin anticoagulant earlier inclusion CLARICOR Trial participation another drug trial within four week participation clinical trial within one month trial individual incapable manage affair able sign write consent lack write consent woman childbearing age use reliable contraceptive breast feed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Coronary heart disease</keyword>
	<keyword>Clarithromycin</keyword>
	<keyword>Macrolides</keyword>
	<keyword>Cardiovascular mortality</keyword>
	<keyword>Chlamydia pneumoniae</keyword>
</DOC>